Atopic Dermatitis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
MARKET OUTLOOK
• Atopic dermatitis is described as the most common type of eczema. The patients suffering from this disease are known to have super sensitive skin and also a decreased threshold for irritation. Also, it misguides the immune system that will lead to chronic diseases.
• The occurrence of atopic dermatitis is common worldwide, especially in infants and children. Atopic dermatitis includes hay fever, food allergies, anaphylaxis, atopic dermatitis, and allergic asthma. Atopic dermatitis has various patterns depending on the age of patients and can occur in the inside of the elbows, knees, sides of the neck, ankles, wrists, and hands and has the tendency to develop papules, which leads to rashes.
• It is characterized by a low quantity of filaggrin protein. Additionally, the skin is very susceptible to infections, such as herpes simplex, staphylococcal and streptococcal bacterial skin infections, warts, and molluscum contagiosum.
• Allergy plays a significant role in patients with atopic dermatitis. The disease mostly occurs when the patient is near to the things that will cause allergic reactions.
• The food allergy is mostly highly arguable in atopic dermatitis from decades, including some common foods like milk, soy, and egg. The major cause for atopic dermatitis of the human body also includes the malfunction in their immune system.
• In addition, some of the factors include skin irritants due to the usage of certain soaps, perfumes, detergents, etc. are. The type of drugs used is a hormone, Erythropoietin, Interferon, Monoclonal antibodies, Calcitonin, and others. It is known to cause blood disorders, Cancer, infectious diseases, chronic diseases, and others.
• The atopic dermatitis market growth is mainly attributed to the increasing occurrence of atopic disorders, and also decreased the quantity of protein filaggrin in the skin. Atopic dermatitis also called as atopic eczema is commonly related to a ‘skin condition’ as a misconception, where it is misunderstood to be self-dealt. However, it impacts the patient life both physically and emotionally.
• The market mostly consists of topical treatment, steroids, and calcineurin inhibitors. Strong pipeline molecules such as ABT-494, apremilast, LY-3009104, GSK-2894512, REGN-668, GBR-830, MEDI-9929, nemolizumab, OPA-15406, PF-04965842, secukinumab, and tralokinumab are expected to show dermatitis treatment market growth over the forecast period.
• An equal number of studies is found to be phase 2 and phase 3 clinical trial developments of drugs for treating atopic dermatitis including Baricitinib by Eli Lilly and Incyte Corporation, Upadacitinib by AbbVie. Novartis entered into a unique license agreement with biotech companies Galapagos NV, Munich, Mechelen, and MorphoSys AG, for the global development and providing marketing rights to MOR106, a novel antibody. Vasomune Therapeutics and AnGes, Inc collaborated to advance novel platform with vascular dysfunction.
• Other factors driving this market are rich pipeline portfolio with products in advanced stages of clinical development, increasing government funds to support research for this disease, and rising campaigns to raise eczema awareness. The allergic reactions particularly due to food are one major factor increasing the burden of atopic dermatitis and drive this market.
• The higher disease severalty was related to greater clinical and economic weight, which acts as one of the major hindrances for the atopic dermatitis market growth. Further, advancing technology in using medical devices is going to add fuel to the market growth. Another significant restraint involved in the scope of the study is serious side effects associated with certain therapeutic drugs.
• Atopic dermatitis is described as the most common type of eczema. The patients suffering from this disease are known to have super sensitive skin and also a decreased threshold for irritation. Also, it misguides the immune system that will lead to chronic diseases.
• The occurrence of atopic dermatitis is common worldwide, especially in infants and children. Atopic dermatitis includes hay fever, food allergies, anaphylaxis, atopic dermatitis, and allergic asthma. Atopic dermatitis has various patterns depending on the age of patients and can occur in the inside of the elbows, knees, sides of the neck, ankles, wrists, and hands and has the tendency to develop papules, which leads to rashes.
• It is characterized by a low quantity of filaggrin protein. Additionally, the skin is very susceptible to infections, such as herpes simplex, staphylococcal and streptococcal bacterial skin infections, warts, and molluscum contagiosum.
• Allergy plays a significant role in patients with atopic dermatitis. The disease mostly occurs when the patient is near to the things that will cause allergic reactions.
• The food allergy is mostly highly arguable in atopic dermatitis from decades, including some common foods like milk, soy, and egg. The major cause for atopic dermatitis of the human body also includes the malfunction in their immune system.
• In addition, some of the factors include skin irritants due to the usage of certain soaps, perfumes, detergents, etc. are. The type of drugs used is a hormone, Erythropoietin, Interferon, Monoclonal antibodies, Calcitonin, and others. It is known to cause blood disorders, Cancer, infectious diseases, chronic diseases, and others.
• The atopic dermatitis market growth is mainly attributed to the increasing occurrence of atopic disorders, and also decreased the quantity of protein filaggrin in the skin. Atopic dermatitis also called as atopic eczema is commonly related to a ‘skin condition’ as a misconception, where it is misunderstood to be self-dealt. However, it impacts the patient life both physically and emotionally.
• The market mostly consists of topical treatment, steroids, and calcineurin inhibitors. Strong pipeline molecules such as ABT-494, apremilast, LY-3009104, GSK-2894512, REGN-668, GBR-830, MEDI-9929, nemolizumab, OPA-15406, PF-04965842, secukinumab, and tralokinumab are expected to show dermatitis treatment market growth over the forecast period.
• An equal number of studies is found to be phase 2 and phase 3 clinical trial developments of drugs for treating atopic dermatitis including Baricitinib by Eli Lilly and Incyte Corporation, Upadacitinib by AbbVie. Novartis entered into a unique license agreement with biotech companies Galapagos NV, Munich, Mechelen, and MorphoSys AG, for the global development and providing marketing rights to MOR106, a novel antibody. Vasomune Therapeutics and AnGes, Inc collaborated to advance novel platform with vascular dysfunction.
• Other factors driving this market are rich pipeline portfolio with products in advanced stages of clinical development, increasing government funds to support research for this disease, and rising campaigns to raise eczema awareness. The allergic reactions particularly due to food are one major factor increasing the burden of atopic dermatitis and drive this market.
• The higher disease severalty was related to greater clinical and economic weight, which acts as one of the major hindrances for the atopic dermatitis market growth. Further, advancing technology in using medical devices is going to add fuel to the market growth. Another significant restraint involved in the scope of the study is serious side effects associated with certain therapeutic drugs.
